{"nctId":"NCT04296396","briefTitle":"Opioid Prescription After Cesarean Trial","startDateStruct":{"date":"2020-09-21","type":"ACTUAL"},"conditions":["Pregnancy Related","Opioid Use","Pain"],"count":5521,"armGroups":[{"label":"Individualized Opioid Prescription","type":"EXPERIMENTAL","interventionNames":["Drug: 0 to 20 tablets of oxycodone 5mg"]},{"label":"Fixed Opioid Prescription","type":"OTHER","interventionNames":["Drug: Fixed opioid prescription"]}],"interventions":[{"name":"0 to 20 tablets of oxycodone 5mg","otherNames":[]},{"name":"Fixed opioid prescription","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Post cesarean delivery (combined vaginal/cesarean deliveries are not eligible)\n* Singleton, twin or triplet gestation\n\nExclusion Criteria:\n\n* An opioid prescription filled during the current pregnancy\n* Known history of opioid use disorder, by medical record review\n* Contraindication to opioids (oxycodone)\n* Contraindications to both acetaminophen and ibuprofen\n* Significant surgical procedures (e.g., hysterectomy) prior to randomization as pain trajectory will be completely different\n* Fetal or neonatal death prior to randomization\n* Inability to randomize within 1 day before planned discharge from the hospital\n* Inability to participate in shared decision making as assessed by research staff\n* Language barrier (non-English or Spanish speaking)\n* Participation in this trial in a previous pregnancy\n* Participation in another intervention study that influences the primary outcome in this trial","healthyVolunteers":false,"sex":"FEMALE","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With Worst Pain Score of Moderate to Severe on the Brief Pain Inventory","description":"Number of participants with moderate to severe pain at 1 week post-discharge; moderate to severe pain is defined as a value of 4 or higher on the \"Worst Pain\" question of the Brief Pain Inventory (BPI) in the last 24 hours. The BPI measures pain severity on a numeric scale of 0 to 10, with 0 being no pain and 10 being the highest level of pain.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1497","spread":null},{"groupId":"OG001","value":"1535","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Who Filled One or More Opioid Prescriptions Beyond the Amount Prescribed at Discharge","description":"Number of participants who filled one or more opioid prescriptions beyond what was prescribed to them at discharge - measured at ninety days postpartum","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"200","spread":null},{"groupId":"OG001","value":"166","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Opioid Prescriptions Filled","description":"Number of opioid prescriptions filled by ninety days postpartum","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"601","spread":null},{"groupId":"OG001","value":"452","spread":null}]},{"measurements":[{"groupId":"OG000","value":"1873","spread":null},{"groupId":"OG001","value":"2086","spread":null}]},{"measurements":[{"groupId":"OG000","value":"163","spread":null},{"groupId":"OG001","value":"140","spread":null}]},{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"16","spread":null}]},{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Opioid Tablets Unused Since Discharge","description":"Number of opioid tablets unused from discharge to 90 days postpartum","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Morphine Milligram Equivalents Used at 2 Weeks Post Discharge","description":"Total morphine milligram equivalents (MME) used from discharge to 2 weeks post-discharge. MME is the amount of milligrams of morphine an opioid dose is equal to when prescribed. Calculating MME accounts for differences in opioid drug type and strength.","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22.5","spread":null},{"groupId":"OG001","value":"37.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Worst Pain Severity Score at 2 Weeks Post Discharge","description":"Pain severity scores assessed on the Brief Pain Inventory numeric scale from 0 to 10 at 2 weeks post-discharge. The BPI measures pain severity on a numeric scale of 0 to 10, with 0 being no pain and 10 being the highest level of pain.","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.0","spread":null},{"groupId":"OG001","value":"2.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Pain Interference Score ≥ 4 at 2 Weeks Post Discharge","description":"Pain interference scores ≥ 4 on the Brief Pain Inventory (numeric scale from 0 to 10) at 2 weeks post-discharge. The BPI measures pain severity on a numeric scale of 0 to 10, with 0 being no pain and 10 being the highest level of pain. This outcome asks participants to indicate their pain scores for the week prior to completing the inventory.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"415","spread":null},{"groupId":"OG001","value":"427","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Who Indicated an Improved Global Impression of Change","description":"Number of participants who indicated an improved global impression of change in overall pain at 2 weeks post-discharge. This represents a selection on a multiple choice survey question with the response options: very much improved, much improved, minimally improved, no change, minimally worse, much worse, very much worse.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2436","spread":null},{"groupId":"OG001","value":"2436","spread":null}]}]}]},{"type":"SECONDARY","title":"Infant Hospital Readmissions","description":"Proportion of infants readmitted to the hospital","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"59","spread":null},{"groupId":"OG001","value":"63","spread":null}]}]}]},{"type":"SECONDARY","title":"Maternal Depression Score ≥ 13","description":"The proportion of participants with a score of 13 or higher on the Edinburgh Postnatal Depression Scale. The minimum score is 0 and the maximum score is 30. Higher scores indicate worse outcomes, where persons scoring about 13 are likely to be suffering from a depressive illness. The scale indicates how the respondent has felt during the previous week.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"185","spread":null},{"groupId":"OG001","value":"191","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":133,"n":2748},"commonTop":["Drowsiness"]}}}